Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novex Pharma labeling deferrals

This article was originally published in The Tan Sheet

Executive Summary

Canadian private labeler's deferral requests from OTC labeling final rule for Minoxidil Topical Solution 2% (Pharmacia's Rogaine Regular Strength for Men, Rogaine for Women) and Minoxidil Topical Solution 5% For Men (Rogaine Extra Strength for Men) are "appropriate," considering "the time that it has taken to finalize current FDA Drug Facts template labeling," agency says in Feb. 4 correspondence. Letter responds to Novex' Nov. 15 citizen petition. FDA has indicated it will revise the template for the 2% product; no template exists for the 5% version (1"The Tan Sheet" Dec. 10, 2001, p. 3)...

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts